Researchers from IOCB Prague are furthering the understanding of how medicines work and what it takes to develop their most effective variants. In one current study, they have focused on the disease ...
The typical job of the proteasome, the garbage disposal of the cell, is to grind down proteins into smaller bits and recycle some of those bits and parts. That's still the case, for the most part, but ...
Recent research from the lab of Dr. Nicolas Lehrbach, an Assistant Professor in the Basic Sciences Division at Fred Hutch, discovered that altering nucleotide metabolism may bypass proteasome defects ...
The typical job of the proteasome, the garbage disposal of the cell, is to grind down proteins into smaller bits and recycle some of those bits and parts. That's still the case, for the most part, but ...
Targeted protein degradation (TPD) approaches including PROTAC and molecular glue have revolutionized drug discovery. However, in part due to complication of the ubiquitination and related ...
BERLIN--(BUSINESS WIRE)--Booster Therapeutics, a biotechnology company pioneering a new class of proteasome activator medicines to treat neurodegenerative and other diseases, launched today with the ...
Hexanucleotide expansions in the C9ORF72 gene are the most common genetic cause of amyotrophic lateral sclerosis and frontotemporal dementia, but how the dipeptide repeats (DPRs) translated from the ...
Booster Therapeutics has launched with $15 million in seed financing and a mission to take on the current crop of targeted protein degraders. The Berlin-based biotech is working on a new class of ...
Neuronal membrane proteasomes are labeled with a red compound and appear in a subset of sensory neurons that are labeled with green compound. Note, not all green labeled neurons have the red label, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results